MDAI stock forecast, quote, news & analysis
Spectral AI Inc is an AI company focused on predictive medical diagnostics... Show more
Spectral AI (MDAI) Stock Analysis: Regulatory Milestones and the Path to First Commercial Sales
Key Takeaways
- Spectral AI (MDAI) finished near $1.53 in early November 2026, down roughly 7% from about $1.65 a month earlier, keeping the stock in a relatively contained trading range.
- The company remains pre-commercialization, with most of its revenue tied to its BARDA research and development contract supporting the DeepView System burn indication.
- Recent milestones include a New Technology Add-On Payment (NTAP) application submitted to CMS and the launch of a clinical study supporting label expansion for the DeepView System.
- An FDA De Novo submission for the DeepView System remains under review, a key step toward the company's first commercial sales.
- Spectral AI trades with a market capitalization near $49 million and a 52-week range of roughly $1.18 to $2.97.
- For additional detail, review MDAI's Price Targets, Earnings, and Forecast pages.
- Explore automated trading strategies with Tickeron's Trending AI Robots.
Current Market Snapshot
Spectral AI shares have traded in a comparatively narrow band over the trailing month, closing around $1.53 in early November 2026 after sitting near $1.65 in early October. The move represents a decline of roughly 7% over a 30-day window, with daily trading volumes fluctuating between roughly 30,000 and more than 180,000 shares. The stock carries a market capitalization near $49 million and a 52-week range of approximately $1.18 to $2.97, reflecting the volatility typical of a small-cap, pre-revenue medical technology company.
Sentiment around the name remains tied to its regulatory and commercialization pipeline rather than current earnings power. With limited institutional coverage and a single tracked analyst, price discovery is heavily influenced by company announcements, contract developments, and broader appetite for speculative healthcare and artificial intelligence names.
Spectral AI (MDAI) Business Overview and Competitive Position
Spectral AI, Inc. is a Dallas, Texas-based artificial intelligence company focused on predictive medical diagnostics. Its flagship product, the DeepView System, combines proprietary multispectral imaging with AI algorithms to assess wound tissue at the initial point of presentation and deliver a binary prediction of whether a wound is likely to heal by a specified future time. The technology is designed to help physicians make faster, more informed treatment decisions, with the primary focus on burn wounds and an expansion path toward diabetic foot ulcers and other chronic wounds.
The company has not yet generated meaningful commercial product revenue. Instead, its revenue has been driven largely by government research and development funding, including a contract with the Biomedical Advanced Research and Development Authority (BARDA) supporting the burn indication. Investors follow MDAI because of the potentially large addressable wound-care market and the regulatory catalysts that could transition the business from R&D-funded to commercially driven over the coming quarters.
Recent Developments Driving MDAI
Several verified milestones have shaped investor attention in recent weeks. In early October 2026, Spectral AI announced the submission of a New Technology Add-On Payment (NTAP) application to the Centers for Medicare & Medicaid Services (CMS) for the DeepView System, a step aimed at securing additional reimbursement for hospitals using the technology. Around the same time, the company completed its first Site Initiation Visit for a clinical study designed to support label expansion of the DeepView System to burns of the head, hands, and feet.
The company also showcased the DeepView System at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly and presented at the ACS Clinical Congress 2026, highlighting the use of AI and multispectral imaging in burn wound assessment. These developments come as Spectral AI's FDA De Novo submission remains under review, with management signaling that commercial activities could begin in earnest following a potential approval. Third-quarter 2026 financial results were scheduled for release in November 2026.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a much larger pool that spans thousands of tickers and hundreds of automated strategies. Only the top-performing and most relevant bots are highlighted in this section, giving traders a focused view of strategies that have recently demonstrated strength. The bots vary widely in approach, holding timeframe, and performance metrics, so the section is best used as a starting point for research rather than a one-size-fits-all signal. Investors tracking names like MDAI can use the page to explore how automated systems are positioning across different market conditions.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important factor for MDAI is the FDA's decision on its De Novo submission for the DeepView System. A positive determination would clear the way for the company's first commercial sales and potentially reshape its revenue profile, which is currently dominated by BARDA-related R&D funding. The outcome of the CMS NTAP application is another key catalyst, since incremental reimbursement could support hospital adoption.
Investors should also monitor the company's cash position and financing needs, the progress of its handheld device development under the MTEC contract, and its international commercialization plans in markets such as the United Kingdom, Australia, and the Gulf Cooperation Council nations. Quarterly revenue trends tied to the BARDA contract, operating expense discipline, and any updates to analyst expectations will remain closely watched, given the stock's limited coverage and sensitivity to news flow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MDAI's RSI Indicator recovers from oversold territory
The RSI Oscillator for MDAI moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 18 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 63 cases where MDAI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MDAI as a result. In 68 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for MDAI just turned positive on November 09, 2026. Looking at past instances where MDAI's MACD turned positive, the stock continued to rise in 34 of 49 cases over the following month. The odds of a continued upward trend are 69%.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDAI advanced for three days, in 136 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
MDAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MDAI moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDAI crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for MDAI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.978) is normal, around the industry mean (4.142). P/E Ratio (-4.656) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.078) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MDAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices